Based on the M1 Kliniken AG stock forecast from 0 analysts, the average analyst target price for M1 Kliniken AG is not available over the next 12 months. M1 Kliniken AG’s average analyst rating is not available. Stock Target Advisor’s own stock analysis of M1 Kliniken AG is Slightly Bullish , which is based on 11 positive signals and 6 negative signals. At the last closing, M1 Kliniken AG’s stock price was EUR 13.45. M1 Kliniken AG’s stock price has changed by -2.89% over the past week, +2.28% over the past month and +71.56% over the last year.
No recent analyst target price found for M1 Kliniken AG
No recent average analyst rating found for M1 Kliniken AG
Company Overview M1 Kliniken AG
M1 Kliniken AG, together with its subsidiaries, provides aesthetic medicine and plastic surgery services in Germany, Austria, the Netherlands, Switzerland, the United Kingdom, Croatia, Hungary, and Australia. The company operates in two segments, Beauty and Trade. It offers aesthetic medical treatments under the M1 Med Beauty brand name across specialist centres; offers surgery services, such as breast augmentation, eyelid lifts, and liposuction; and other aesthetic medical treatment services, including injections with hyaluronic acid and botulinum toxin, as well as manages a private clinic for plastic and aesthetic surgery under the M1 Schlossklinik brand name. The company also distributes pharmaceutical and medical devices in the therapeutic areas comprising oncology, HIV/AIDS, neurology, rheumatology, and other chronic diseases. M1 Kliniken AG was founded in 2007 and is headquartered in Berlin, Germany. M1 Kliniken AG is a subsidiary of MPH Health Care AG. Address: Grünauer Strasse 5, Berlin, Germany, 12557 Read Less
M1 Kliniken AG, together with its subsidiaries, provides aesthetic medicine and plastic surgery services in Germany, Austria, the Netherlands, Switzerland, the United Kingdom, Croatia, Hungary, and Australia. The company operates in two segments, Beauty and Trade. It offers aesth...Read More
Frequently Asked Questions About M1 Kliniken AG (M12:XETRA) Stock
Stock Target Advisor's fundamental analysis for M1 Kliniken AG's stock is Slightly Bullish .
Unfortunately we do not have enough data on M12:XETRA's stock to indicate if its a good dividend stock.
Unfortunately we do not have enough data on M12:XETRA's stock to indicate what its average analyst target is.
M12:XETRA stock's Price/Earning ratio is 41.72.
Our analysis grades M12:XETRA stock's Price / Earning ratio at F. This means that M12:XETRA stock's Price/Earning ratio is above 57.00000000000001% of the stocks in the Medical Care Facilities sector in the XETRA exchange.
Based on this M12:XETRA may be a overvalued for its sector.
The last closing price of M12:XETRA's stock was EUR 13.45.
The most recent market capitalization for M12:XETRA is EUR 0.24B.
Unfortunately we do not have enough analyst data on M12:XETRA's stock to indicate whether its price will go up or not.
We can't find any ETFs which contains M1 Kliniken AG's stock.
As per our most recent records M1 Kliniken AG has 366 Employees.
M1 Kliniken AG's registered address is Grünauer Strasse 5, Berlin, Germany, 12557.
You can get more information about it from M1 Kliniken AG's website at https://www.m1-kliniken.de.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
Low debt
The company is less leveraged than its peers ,, and is among the top quartile, which makes it more flexible. However, do check the news and look at its sector. Sometimes this is low because the company is not growing and has no growth potential.
Superior risk adjusted returns
This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.
Positive cash flow
The company had positive total cash flow in the most recent four quarters.
Positive free cash flow
The company had positive total free cash flow in the most recent four quarters.
Superior return on assets
The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.
Superior capital utilization
The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.
Superior Revenue Growth
This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.
Superior Earnings Growth
This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.
Superior Dividend Growth
This stock has shown top quartile dividend growth in the previous 5 years compared to its sector
High dividend returns
The stock has outperformed its sector peers on average annual dividend returns basis in the past 5 years (for a hold period of at least 12 months) and is in the top quartile. This can be a good buy, especially if it is outperforming on total return basis , for investors seeking high income yields.
Superior return on equity
The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.
What not to like
Overpriced compared to book value
The stock is trading high compared to its peers median on a price to book value basis.
Overpriced compared to earnings
The stock is trading high compared to its peers on a price to earning basis and is above the sector median.
Below median total returns
The company has under performed its peers on annual average total returns in the past 5 years.
High volatility
The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.
Overpriced on cashflow basis
The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
Overpriced on free cash flow basis
The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for M12:XETRA !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
Stocktwits
